• Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    Source: Nasdaq GlobeNewswire / 02 Jan 2024 07:00:20   America/Chicago

    NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.

    The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

    About Intra-Cellular Therapies

    Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

    Contact:

    Intra-Cellular Therapies, Inc.
    Juan Sanchez, M.D.
    Vice President, Corporate Communications and Investor Relations
    646-440-9333

    Burns McClellan, Inc.
    Cameron Radinovic
    cradinovic@burnsmc.com
    212-213-0006


    Primary Logo

Share on,